2Aoyama K, Kamio T, Nishikawa T, et al. A comparison of HERZ/neu gene coamplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Jpn J Clin Oncol, 2010, 40: 613-619.
3Hansel DE, Swain E, Dreicer R, et al. HER-2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplificatian in a subset of cases. Am J Clin Pathol, 2008, 130: 274-281.
4Clavarezza M, Venturini M. Adjuvant chemotherapy for the treatment of HER-2 positive early breast cancer. Oncology, 2009, 77: 14-17.
5Chang J, Clark GM, Aured DC, et al. Survival of patients with metastatic breast carcinoma:importance of prognostic markers of the primary tumor. Cancer, 2003, 79: 545-553.
6Beenken SW, Grizzle WE, Crowe DR, et al. Molercular biomarkers for breast cancer prognosis:coexpression of c-erbB-2 and p53. Ann Surg, 2001, 233: 630-638.
7Gaci Z, Bouin-Pineau MH, Gaci M, et al. Prognostic impact of cathepsin D and c-cerbB-2 oncoprotein in a subgroup of node-negative breast cancer patient with low histological grade tumors. Int J Oncol, 2001, 18: 793-800.
8Scorilas A, Trangas T, Yotis J, et al. Determination of c- myc amplification and overexpression in breat cancer patients: evaluation of its prognostic value against c - erbB - 2 , cathepsin - D and clinicopathological characteristics using univariate anal
9Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer, 2003,97(3):545-553.
